Ignite Creation Date:
2025-12-24 @ 11:41 PM
Ignite Modification Date:
2026-01-03 @ 10:37 AM
Study NCT ID:
NCT07165951
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2025-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Sponsor:
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TQB2868-ALTN-III-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None